JP2024512808A - Ｃａｌｒ及びｊａｋ２ｔ細胞受容体 - Google Patents

Ｃａｌｒ及びｊａｋ２ｔ細胞受容体 Download PDF

Info

Publication number
JP2024512808A
JP2024512808A JP2023561124A JP2023561124A JP2024512808A JP 2024512808 A JP2024512808 A JP 2024512808A JP 2023561124 A JP2023561124 A JP 2023561124A JP 2023561124 A JP2023561124 A JP 2023561124A JP 2024512808 A JP2024512808 A JP 2024512808A
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
seq
cdr3
alpha chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512808A5 (https=
Inventor
ハンソン，レベッカ
クリシュナ，ヴィノッド
アレジャンドロ セプルヴェダ，マニュエル
ウィルキンソン，パトリック
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2024512808A publication Critical patent/JP2024512808A/ja
Publication of JP2024512808A5 publication Critical patent/JP2024512808A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023561124A 2021-04-05 2022-04-04 Ｃａｌｒ及びｊａｋ２ｔ細胞受容体 Pending JP2024512808A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170711P 2021-04-05 2021-04-05
US63/170,711 2021-04-05
PCT/US2022/023238 WO2022216574A1 (en) 2021-04-05 2022-04-04 Calr and jak2 t-cell receptors

Publications (2)

Publication Number Publication Date
JP2024512808A true JP2024512808A (ja) 2024-03-19
JP2024512808A5 JP2024512808A5 (https=) 2025-04-11

Family

ID=83546460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561124A Pending JP2024512808A (ja) 2021-04-05 2022-04-04 Ｃａｌｒ及びｊａｋ２ｔ細胞受容体

Country Status (4)

Country Link
US (1) US20230079750A1 (https=)
EP (1) EP4320144A4 (https=)
JP (1) JP2024512808A (https=)
WO (1) WO2022216574A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3947700A4 (en) 2019-04-01 2023-01-04 Tenaya Therapeutics, Inc. Adeno-associated virus with engineered capsid
BR112023006305A2 (pt) 2020-10-09 2023-05-09 Tenaya Therapeutics Inc Métodos e composições de terapia gênica com placofilina-2
WO2024259371A2 (en) * 2023-06-14 2024-12-19 Duke University COMPOSITIONS FOR AND METHODS OF EXPANDING γδ T CELLS
CN118747324B (zh) * 2024-06-11 2024-12-27 扬州大学 一种基于时频复合递归图的直流电弧故障检测方法和系统
CN118834299B (zh) * 2024-09-24 2025-04-25 康立泰生物医药(青岛)有限公司 一种抗tslp的鲨鱼纳米抗体融合蛋白及其生产方法、检测试剂盒和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517544A (ja) * 2016-06-10 2019-06-24 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃａｌｒ及びｊａｋ２ワクチン組成物
JP2020517308A (ja) * 2017-04-24 2020-06-18 オスペダーレ サン ラファエレ エス．アール．エル Ｔｃｒ及びペプチド

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016095783A1 (zh) * 2014-12-17 2016-06-23 中国科学院广州生物医药与健康研究院 识别eb病毒短肽的t细胞受体
MX2019003768A (es) * 2016-10-03 2019-06-24 Juno Therapeutics Inc Moleculas de enlace especificas de hpv.
US20210147550A1 (en) * 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
JP2021533777A (ja) * 2018-08-16 2021-12-09 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
EP3962939A4 (en) * 2019-05-03 2023-05-17 Gigamune, Inc. MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM
CR20220220A (es) * 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019517544A (ja) * 2016-06-10 2019-06-24 アイオー バイオテック エーピーエスＩＯ Ｂｉｏｔｅｃｈ ＡｐＳ Ｃａｌｒ及びｊａｋ２ワクチン組成物
JP2020517308A (ja) * 2017-04-24 2020-06-18 オスペダーレ サン ラファエレ エス．アール．エル Ｔｃｒ及びペプチド

Also Published As

Publication number Publication date
WO2022216574A1 (en) 2022-10-13
US20230079750A1 (en) 2023-03-16
EP4320144A4 (en) 2025-04-09
EP4320144A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
JP2024512808A (ja) Ｃａｌｒ及びｊａｋ２ｔ細胞受容体
CA2567254C (en) Tc-83-derived alphavirus vectors, particles and methods
JP5602624B2 (ja) αウイルス構造タンパク質の発現のためのプロモーターレスカセット
Schlesinger Alphavirus vectors: development and potential therapeutic applications
Frolov et al. Alphavirus-based expression vectors: strategies and applications.
JP5268196B2 (ja) キメラアルファウイルスレプリコン粒子
Anraku et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity
JP2001519165A (ja) 細胞巨大分子合成の阻害が低減された組換えアルファウイルスベースのベクター
JP7701080B2 (ja) アルファウイルスレプリコン粒子
JPH09503657A (ja) 組換えアルファウイルスベクター
JP2005515755A5 (https=)
JP2001521369A (ja) 細胞巨大分子合成の阻害が減少したアルファウイルスベクター
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
Lundstrom Alphavirus vectors for gene therapy applications
Lundstrom Alphaviruses as expression vectors
Lundstrom et al. Semliki Forest virus vectors for in vitro and in vivo applications
TW202120533A (zh) 基於突變體ｃａｌｒ及ｊａｋ２之疫苗及其等之用途
US20040253271A1 (en) Live attenuated viral vaccines for Eastern equine encephalitis virus

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203